SCHEMBL6916751

SCHEMBL6916751

CCCCOc1cc(-c2nccc(-c3ccccc3)n2)cn(C)c1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
L3MBTL1 Q9Y468 3/20 0.46
KDM4E B2RXH2 1/20 0.46
BCHE P06276 1/20 0.40
ACHE P22303 1/20 0.40
BRD4 O60885 3/20 0.39
CREBBP Q92793 2/20 0.39
TLR8 Q9NR97 3/20 0.38
ALDH1A1 P00352 5/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP19A1 P11511 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
LMNA P02545 2/20 0.37
NPY1R P25929 1/20 0.37
NPY2R P49146 1/20 0.37
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2467660 0.85 BRD4 (0.44) MAPTMEN1KMT2AL3MBTL1KDM4E
SCHEMBL6915411 0.80 BRD4 (0.49) MEN1KMT2AKDM4EBCHEACHE
SCHEMBL2440533 0.77 COMT (0.44) MAPTMEN1KMT2AKDM4EBRD4
SCHEMBL6915482 0.67 PTPN1 (0.38) MAPTMEN1KMT2AKDM4EBRD4
SCHEMBL15614531 0.66 TLR8 (0.46) MAPTL3MBTL1KDM4EBCHEACHE
SCHEMBL29620532 0.65 AURKA (0.63) MAPTMEN1KMT2AL3MBTL1KDM4E
SCHEMBL190954 0.65 AURKA (0.63) MAPTMEN1KMT2AL3MBTL1KDM4E
SCHEMBL10689392 0.65 MAPT (0.64) MAPTMEN1KMT2AL3MBTL1KDM4E
SCHEMBL28113169 0.64 CYP2D6 (0.62) MAPTMEN1KMT2AL3MBTL1KDM4E
SCHEMBL2466390 0.64 BRD4 (0.52) MAPTL3MBTL1KDM4EBRD4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9309199-B2 Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders MERCK SHARP & DOHME CORP. (US) 2016-04-12 US disclosed
US-20130005744-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS MERCK SHARP & DOHME LLC 2013-01-03 US disclosed
WO-2011109261-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS MERCK SHARP & DOHME CORP. (US) 2011-09-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130005744-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS COMT, PNMT, TPMT MAPT 220/4885MEN1 4425/4885KMT2A 317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.